Fractionated Irradiation Induced Radio-resistant Esophageal Cancer EC109 Cells Seem to Be More Sensitive to Chemotherapeutic Drugs

Overview

Journal J Exp Clin Cancer Res

Publisher Biomed Central

Specialty Oncology

Date 2009 May 28

PMID 19470182

Citations 12

Authors

Li Xie

Xianrang Song

Jinming Yu

Ling Wei

Bao Song

Xingwu Wang

Liyan Lv

Affiliations

Soon will be listed here.

Abstract

Background: Chemo-radiotherapy, a combination of chemotherapy and radiotherapy, is the most frequent treatment for patients with esophageal cancer. In the process of radiotherapy, the radiosensitive cancer will become a radio-resistant one.

Methods: In order to detect the chemotherapeutic drug sensitivity in radio-resistant cancer cells and improve the therapy efficiency, we firstly established a radio-resistant esophageal cancer cell model (referred to as EC109/R) from the human esophageal squamous cell carcinoma cell line EC109 through fractionated irradiation using X-rays. The radio-sensitivity of EC109/R cells was measured by clonogenic assay. To detect the drug sensitivity for EC109/R compared to its parent cells, we employed MTT method to screen the effectiveness of five different drugs commonly used in clinical therapy. The ratio of apoptosis was examined by flow cytometry.

Results: EC109/R cells were more sensitive to 5-fluorouracil, doxorubicin, paclitaxel and etoposide, but tolerant to cisplatin compared to its original cells.

Conclusion: Our study implies that fractionated irradiation induced radio-resistant esophageal cancer cell is more sensitive to certain kind of chemotherapeutic drugs. It provides evidence for choosing the sequence of radiotherapy and chemotherapy in esophageal cancer.

Citing Articles

Cancer-associated fibroblast-derived gene signatures predict radiotherapeutic survival in prostate cancer patients.

Zhang R, Liu F J Transl Med. 2022; 20(1):453.

PMID: 36195908 PMC: 9533530. DOI: 10.1186/s12967-022-03656-5.

Downregulation of breast cancer resistance protein by long-term fractionated radiotherapy sensitizes lung adenocarcinoma to SN-38.

Wang Y, Huang J, Wu Q, Zhang J, Ma Z, Ma S Invest New Drugs. 2021; 39(2):458-468.

PMID: 33475937 DOI: 10.1007/s10637-020-01003-3.

Mechanisms of different response to ionizing irradiation in isogenic head and neck cancer cell lines.

Todorovic V, Prevc A, Zakelj M, Savarin M, Brozic A, Groselj B Radiat Oncol. 2019; 14(1):214.

PMID: 31775835 PMC: 6882348. DOI: 10.1186/s13014-019-1418-6.

Electrochemotherapy of radioresistant head and neck squamous cell carcinoma cells and tumor xenografts.

Zakelj M, Prevc A, Kranjc S, Cemazar M, Todorovic V, Savarin M Oncol Rep. 2019; 41(3):1658-1668.

PMID: 30628709 PMC: 6365705. DOI: 10.3892/or.2019.6960.

Clinically relevant radioresistant cell line: a simple model to understand cancer radioresistance.

Kuwahara Y, Roudkenar M, Urushihara Y, Saito Y, Tomita K, Roushandeh A Med Mol Morphol. 2017; 50(4):195-204.

PMID: 29067564 DOI: 10.1007/s00795-017-0171-x.

References

Brenner B, Ilson D, Minsky B . Treatment of localized esophageal cancer. Semin Oncol. 2004; 31(4):554-65. DOI: 10.1053/j.seminoncol.2004.04.015. View

Carcaterrra M, Osti M, De Sanctis V, Caruso C, Berardi F, Maurizi Enrici R . Adjuvant radiotherapy and radiochemotherapy in the management of esophageal cancer: a review of the literature. Rays. 2006; 30(4):319-22. View

Ku G, Ilson D . Preoperative therapy in esophageal cancer. Clin Adv Hematol Oncol. 2008; 6(5):371-9. View

Suit H . The Gray Lecture 2001: coming technical advances in radiation oncology. Int J Radiat Oncol Biol Phys. 2002; 53(4):798-809. DOI: 10.1016/s0360-3016(02)02851-1. View

Liao Z, Cox J, Komaki R . Radiochemotherapy of esophageal cancer. J Thorac Oncol. 2007; 2(6):553-68. DOI: 10.1097/01.JTO.0000275339.62831.5e. View

Ogawa K, Utsunomiya T, Mimori K, Tanaka F, Haraguchi N, Inoue H . Differential gene expression profiles of radioresistant pancreatic cancer cell lines established by fractionated irradiation. Int J Oncol. 2006; 28(3):705-13. View

Nielsen D, Maare C, Eriksen J, Litman T, Skovsgaard T . Expression of P-glycoprotein and multidrug resistance associated protein in Ehrlich ascites tumor cells after fractionated irradiation. Int J Radiat Oncol Biol Phys. 2001; 51(4):1050-7. DOI: 10.1016/s0360-3016(01)01719-9. View

Wright C . Esophageal cancer surgery in 2005. Minerva Chir. 2006; 60(6):431-44. View

Hill B, Moran E, Etievant C, Perrin D, Masterson A, Larkin A . Low-dose twice-daily fractionated X-irradiation of ovarian tumor cells in vitro generates drug-resistant cells overexpressing two multidrug resistance-associated proteins, P-glycoprotein and MRP1. Anticancer Drugs. 2000; 11(3):193-200. DOI: 10.1097/00001813-200003000-00007. View

10.

Martin L, Hamilton T, Schilder R . Platinum resistance: the role of DNA repair pathways. Clin Cancer Res. 2008; 14(5):1291-5. DOI: 10.1158/1078-0432.CCR-07-2238. View

11.

Law S, Wong J . The current management of esophageal cancer. Adv Surg. 2007; 41:93-119. DOI: 10.1016/j.yasu.2007.05.007. View

12.

Seitz J, Dahan L, Jacob J, Artru P, Maingon P, Bedenne L . Esophagus cancer. Gastroenterol Clin Biol. 2006; 30 Spec No 2:2S5-2S15. View

13.

Ng T, DiPetrillo T, Purviance J, Safran H . Multimodality treatment of esophageal cancer: a review of the current status and future directions. Curr Oncol Rep. 2006; 8(3):174-82. DOI: 10.1007/s11912-006-0017-5. View

14.

Borst P, Rottenberg S, Jonkers J . How do real tumors become resistant to cisplatin?. Cell Cycle. 2008; 7(10):1353-9. DOI: 10.4161/cc.7.10.5930. View

15.

Bottke D, Koychev D, Busse A, Heufelder K, Wiegel T, Thiel E . Fractionated irradiation can induce functionally relevant multidrug resistance gene and protein expression in human tumor cell lines. Radiat Res. 2008; 170(1):41-8. DOI: 10.1667/RR0986.1. View

16.

Xiao Z, Yang Z, Liang J, Miao Y, Wang M, Yin W . Value of radiotherapy after radical surgery for esophageal carcinoma: a report of 495 patients. Ann Thorac Surg. 2003; 75(2):331-6. DOI: 10.1016/s0003-4975(02)04401-6. View

17.

Shimokuni T, Tanimoto K, Hiyama K, Otani K, Ohtaki M, Hihara J . Chemosensitivity prediction in esophageal squamous cell carcinoma: novel marker genes and efficacy-prediction formulae using their expression data. Int J Oncol. 2006; 28(5):1153-62. View

18.

Ahmed K, Dong S, Fan M, Li J . Nuclear factor-kappaB p65 inhibits mitogen-activated protein kinase signaling pathway in radioresistant breast cancer cells. Mol Cancer Res. 2006; 4(12):945-55. DOI: 10.1158/1541-7786.MCR-06-0291. View

19.

Gupta S, Ahmed M . A global perspective of radiation-induced signal transduction pathways in cancer therapeutics. Indian J Exp Biol. 2004; 42(12):1153-76. View

20.

Ku G, Ilson D . Esophageal cancer: adjuvant therapy. Cancer J. 2007; 13(3):162-7. DOI: 10.1097/PPO.0b013e318074dbe7. View